Navigation Links
New developments reveal a molecule with a promising function in terms of cancer treatment.
Date:10/30/2012

Researchers from Inserm and CNRS from the Institute for genetics and molecular and cellular biology (IGBMC) and from the Research Institute at the Strasbourg school of biotechnology (Irebs) have focussed their efforts on PARG, currently thought to be a promising new therapeutic target in the treatment of cancer. Their work has revealed the role of this molecule in regulating gene expression. The results were published on 25 October 2012 in the on-line Molecular Cell review.

Cells are subjected to various stresses throughout their life. Some of this stress can damage DNA. Fortunately, cells have several mechanisms used to repair these lesions. Breaking two DNA strands is one of the most serious afflictions a chromosome can suffer. The cell must repair this break if it is to continue dividing. Repair actions are either performed in an optimal manner, and the cell resumes its normal division cycle, or the lesion is not repaired correctly, causing the cell to die or the appearance of an anomaly that may trigger cancer.

One of the repair mechanisms used is poly(ADP-ribosyl)ation. In this mechanism, some molecules (PARPs) detect DNA breaks and cause poly(ADP-riboses) synthesis that binds with proteins, thus initialising the lesion repair system. As such, this system can act as a 'saviour' if the repairs are correctly completed, but, it can be equally damaging in the event of incorrect repair.

In the case of cancer, to ensure the cells are destroyed, PARP inhibitors are currently undergoing clinical tests as therapeutic adjuvant used to increase the receptivity of cancer cells to specific chemotherapies.

In terms of fundamental research, researchers know that the poly(ADP-ribosyl)ation mechanism is reversible and is closely regulated by Poly(ADP-ribose) glycohydrolase (PARG). PARP and PARG thus seem to make up a tandem of molecules dedicated to maintaining genome integrity. PARG targeting has proved to potentiate the action of genotoxic agents, making this molecule a promising new therapeutic target in the treatment of some cancers, as is the case for PARP.

However, little research has been conducted into PARG, but in light of its close links with PARP, researchers are now taking a very close look at its functions. 2

In this new work, the researchers have demonstrated that in addition to its genome repair role, PARG was involved in modulating the cell's transcriptional activity.

Given the keen current interest on PARP and PARG inhibitors in the treatment of cancer, it is essential to gain accurate knowledge of the functions and action modes of these promising therapeutic targets, as well as the consequences of their invalidation. This study is the first to highlight how PARG action mechanism regulates gene expression.


'/>"/>

Contact: Press
presse@inserm.fr
INSERM (Institut national de la sant et de la recherche mdicale)
Source:Eurekalert

Related medicine news :

1. Attention, parents: UC research reveals a secret about your medicine cabinet
2. Secret of Anesthesia Revealed, Study Says
3. Study reveals teenage patients attitude towards social media and privacy
4. A TECNALIA study reveals the loss of nanomaterials in surface treatments caused by water
5. Researchers reveal underlying mechanism of powerful chemotherapy for prostate cancer treatment
6. Discovery of essential genes for drug-resistant bacteria reveals new, high-value drug targets
7. New software helps reveal patterns in space and time
8. Lack of support for ring-fencing cancer drugs fund revealed
9. Well-known protein reveals new tricks
10. Genome-wide scan maps mutations in deadly lung cancers; reveals embryonic gene link
11. More Benefits of Breast Milk Revealed
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2017)... ... July 23, 2017 , ... ... Pain Relief Group – Melbourne, a practice owned by Physician Partners of America ... pain management, Dr. Stern also is certified in pediatrics, emergency medicine and anesthesiology. ...
(Date:7/23/2017)... ... July 23, 2017 , ... Viora Ltd., a leading ... Patent No. 9,038,640 by the United States Patent and Trademark Office. The patent ... of Switching, Vacuum, and Cooling mechanisms to further increase the efficacy and safety ...
(Date:7/22/2017)... ... July 22, 2017 , ... More than 130,000 Anterior Cruciate ... requiring pain medication after three months post-operatively. However, researchers presenting their work at ... Toronto, Ontario, Canada found that those patients who were filling opioid prescriptions prior ...
(Date:7/21/2017)... ... 21, 2017 , ... "As a doctor of lung medicine managing chest diseases ... the market," said an inventor from Center Valley, Pa. "My idea is to improve ... He developed the patent-pending PLEURAL SAFE-t-STAT CATHETER KIT to offer an efficient means of ...
(Date:7/21/2017)... ... July 21, 2017 , ... ... and financial consultations to communities in the greater Denver region, is announcing a ... diagnosed with a very rare kind of epilepsy. , Until a few months ...
Breaking Medicine News(10 mins):
(Date:7/5/2017)... Wash. , July 5, 2017   BioLife ... leading developer, manufacturer and marketer of proprietary clinical grade ... cryopreservation freeze media ("BioLife"), today announced that it ... its debt holder and largest shareholder, to modify its ... Pursuant to the modification, WAVI agreed to exchange ...
(Date:6/30/2017)... SAN DIEGO , June 30, 2017  AVACEN Medical (AVACEN) ... Access Journal. The research describes the use of its AVACEN ... by those suffering from fibromyalgia. ... AVACEN Medical ... Fibromyalgia is characterized by chronic widespread pain. It affects approximately 200 to ...
(Date:6/27/2017)... , Jun 27, 2017   NuEyes (NuEyes ... of funding to fuel its growth in helping the legally ... (Osterhout Design Group), the leading developer of augmented, virtual ... technology sits. The undisclosed funding amount was provided ... firm, Arab Angel, with offices in Abu Dhabi ...
Breaking Medicine Technology: